Matthew Ronsheim serves as Executive at Entasis Therapeutics Holdings Inc., where they oversee executive responsibilities. Since joining the company, Matthew Ronsheim has executed 11 insider transactions totaling $12.0K, demonstrating a bearish approach to their equity position. Their most recent transaction on May 20, 2024 involved selling 268 shares valued at $4.3K.
Matthew Ronsheim currently holds 40,510 shares of Entasis Therapeutics Holdings Inc. (ETTX), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Matthew Ronsheim has been a net seller of ETTX stock. They have purchased $0 and sold $12.0K worth of shares.
Matthew Ronsheim's most recent insider trade was on May 20, 2024, when they sold 268 shares at $16.13 per share.
Get notified when new Form 4 filings are submitted
| $14.88 |
| Discretionary |
| Feb 20, 2024 | INVA | $12.8K | Payment | 807 | $15.80 | Discretionary |
| Jan 18, 2024 | INVA | $25.7K | Payment | 1,600 | $16.05 | Discretionary |
| Jul 11, 2022 | ETTX | $0 | Disposition | 150,000 | $N/A | Discretionary |
| Jul 7, 2022 | ETTX | $38.7K | Tender | 17,572 | $2.20 | Discretionary |
| Jan 18, 2022 | ETTX | $0 | Award | 125,000 | $N/A | Discretionary |
| Nov 2, 2021 | ETTX | $10.8K | Payment | 3,669 | $2.94 | Discretionary |
| Oct 19, 2021 | ETTX | $0 | Award | 25,000 | $N/A | Discretionary |
| Oct 19, 2021 | ETTX | $12.0K | Sale | 3,759 | $3.19 | Discretionary |
| Jan 15, 2021 | ETTX | $0 | Award | 25,000 | $N/A | Discretionary |